Kidney Disease
Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.
A clinic at Groote Schuur Hospital in Cape Town is providing tailored care for adolescents and young adults with kidney disease, helping them transition from pediatric services. The Kidney Adolescent and Young Adult Clinic, known as Kayac, has shown improved survival rates and lower dropout compared to standard adult care.
AI에 의해 보고됨 사실 확인됨
A large international randomized trial found that 4 grams a day of omega-3 fish oil was associated with a 43% lower rate of serious cardiovascular events among adults receiving maintenance hemodialysis. The PISCES study enrolled 1,228 participants at 26 sites in Australia and Canada; results were presented at the American Society of Nephrology’s Kidney Week 2025 and published in The New England Journal of Medicine.
A Lancet analysis estimates that nearly 800 million adults were living with chronic kidney disease in 2023—up from 378 million in 1990—with the illness now ranking ninth among global causes of death. Researchers urge earlier detection and wider access to proven treatments.
AI에 의해 보고됨
Researchers at University of Utah Health have discovered that ceramides trigger acute kidney injury by damaging mitochondria in kidney cells. Using a drug candidate to alter ceramide metabolism, they completely prevented kidney injury in mice. The findings suggest potential for early biomarkers and preventive treatments in humans.